(d-Ser2)Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions

Biochemical Pharmacology

Volumn 80, Issue 11, 2010, Pages 1727-1735

  Kerr, Barry D ^a   Flatt, Peter R ^a   Gault, Victor A ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

GLP 1; Glucose tolerance; Insulin secretion; Ob ob mouse; Oxyntomodulin

Indexed keywords

ADIPONECTIN; ANOREXIGENIC AGENT; ANTIHYPERTENSIVE AGENT; CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OXYNTOMODULIN; TRIACYLGLYCEROL; (D SER2)OXM(MPEG PAL); (D-SER2)OXM(MPEG-PAL); ANTIDIABETIC AGENT; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; ENZYME DEGRADATION; ENZYME STABILITY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; AMINO ACID SEQUENCE; ANIMAL; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; EATING; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; MOUSE MUTANT; PHYSIOLOGY; SECRETION;

AMINO ACID SEQUENCE; ANIMALS; APPETITE DEPRESSANTS; BLOOD GLUCOSE; CELL LINE; EATING; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, OBESE; MOLECULAR SEQUENCE DATA; OXYNTOMODULIN;

EID: 77957890652     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.08.010     Document Type: Article

References (36)

1. Bloom S.R., Polak J.M. Gut hormones. Adv Clin Chem 1980, 21:177-244.
2. Holst J.J. Enteroglucagon. Annu Rev Physiol 1997, 59:257-271.
3. Drucker D.J. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab 2005, 1:22-31.
4. Dakin C.L., Small C.J., Batterham R.L., Neary N.M., Cohen M.A., Patterson M., et al. Peripheral oxyntomodulin reduces food intake and bodyweight gain in rats. Endocrinology 2004, 145:2687-2695.
5. Wynne K., Park A.J., Small C.J., Meeran K., Ghatei M.A., Frost G.S., et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomized controlled trial. Int J Obes (Lond) 2006, 30:1729-1736.
6. Cohen M.A., Ellis S.M., Le Roux C.W., Batterham R.L., Park A., Patterson M., et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003, 88:4696-4701.
7. Karra E., Batterham R.L. The role of gut hormones in the regulation of body weight and energy homeostasis. Mol Cell Endocrinol 2010, 316:120-128.
8. Maida A., Lovshi J.A., Baggio L.L., Drucker D.J. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances β-cell function but does not inhibit gastric emptying in mice. Endocrinology 2008, 149:5670-5678.
9. Baggio L.L., Huang Q., Brown T.J., Drucker D.J. Oxyntomodulin and glucagon-like peptide 1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004, 127:546-558.
10. Pocai A., Carrington P.E., Adams J.R., Wright M., Eiermann G., Zhu L., et al. GLP-1/GCGR dual agonism reverses obesity in mice. Diabetes 2009, 58:2258-2266.
11. Marks V Glucagon. Clin Endocrinol Metab 1972, 1:829-845.
12. Holst J.J., Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004, 287:E199-E206.
13. Gros L., Thorens B., Bataille D., Kervran A. Glucagon-like peptide-1-(7-36) amide, oxyntomodulin, and glucagon interact with a common receptor in a somatostatin-secreting cell line. Endocrinology 1993, 133:631-638.
14. Day J.W., Ottaway N., Patterson J.T., Gelfanov V., Smiley D., Gidda J., et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009, 5:749-757.
15. Druce M.R., Minnion J.S., Field B.C., Patel S.R., Shillito J.C., Tilby M., et al. Investigation of structure-activity relationships of oxyntomodulin (Oxm) using Oxm analogs. Endocrinology 2009, 150:1712-1721.
16. Mentlein S R Dipeptidyl-peptidase IV (CD26)-role of inactivation of regulatory peptides. Regul Pept 1999, 85:9-24.
17. Irwin N., Flatt P.R., Gault V.A. GIP-based therapeutics for diabetes and obesity. Curr Chem Biol 2008, 2:61-68.
18. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)-preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009, 23:463-477.
19. Deacon C.F., Knudsen L.B., Madsen K., Wiberg F.C., Jacobsen O., Holst J.J. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 1998, 41:271-278.
20. Gault V.A., Flatt P.R., Harriott P., Mooney M.H., Bailey C.J., O'Harte F.P. Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotropic polypeptide. J Endocrinol 2002, 176:133-141.
21. Hinke S.A., Gelling R.W., Pederson R.A., Manhart S., Nian C., Demuth H.U., et al. Dipeptidyl peptidase IV-resistant [d-Ala(2)]glucose-dependent insulontropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 2002, 51:652-661.
22. Green B.D., Lavery K.S., Irwin N., O'Harte F.P., Harriott P., Greer B., et al. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. J Pharmacol Exp Ther 2006, 318:914-921.
23. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., Johansen N.L., Madsen K., Pedersen F.Z., et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000, 43:1664-1669.
24. Gault V.A., Kerr B.D., Irwin N., Flatt P.R. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. Biochem Pharmacol 2008, 75:2325-2333.
25. Green B.D., Gault V.A., Mooney M.H., Irwin N., Harriott P., Greer B., et al. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues. Biol Chem 2004, 385:169-177.
26. Lee S., Youn Y.S., Lee S.H., Byun Y., Lee K.C. PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice. Diabetologia 2006, 49:1608-1611.
27. Kerr B.D., Irwin N., O'Harte F.P., Bailey C.J., Flatt P.R., Gault V.A. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Biochem Pharmacol 2009, 78:1008-1016.
28. McClenaghan N.H., Barnett C.R., Ah-Sing E., Abdel-Wahab Y.H., O'Harte F.P., Yoon T.W., et al. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electro-fusion. Diabetes 1996, 45:1132-1140.
29. Thorens B., Porret A., Buhler L., Deng S.P., Morel P., Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42:1678-1682.
30. Reeves P.J., Kim J.M., Khorana H.G. Structure and function in rhodopsin: a tetracycline-inducible system in stable mammalian cell lines for high-level expression of opsin mutants. Proc Natl Acad Sci U S A 2002, 99:13413-13418.
31. Bailey C.J., Flatt P.R. Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int J Obes 1982, 6:11-21.
32. Flatt P.R., Bailey C.J. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 1981, 20:573-577.
33. Jayasena C.N., Bloom S.R. Role of gut hormones in obesity. Endocrinol Metab Clin North Am 2008, 37:769-787.
34. Dakin C.L., Small C.J., Park A.J., Seth A., Ghatei M.A., Bloom S.R. Repeated ICV administration of oxyntomodulin causes a greater reduction in bodyweight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 2002, 283:E1173-E1177.
35. Flatt P.R., Bailey C.J., Green B.D. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front Biosci 2008, 13:3648-3660.
36. Creutzfeldt W. The entero-insular axis in type 2 diabetes-incretins as therapeutic agents. Exp Clin Endocrinol Diabetes 2001, 109:S288-S303.